Cyclophosphamide Anhydrous

Summary

Cyclophosphamide Anhydrous (CHEMBL88) is an approved small-molecule alkylating agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 3,334
• Chemistry: 261.08 Da · C7H15Cl2N2O2P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL88
Name	Cyclophosphamide Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2907
ChEBI	CHEBI:4027
Molecular formula	C7H15Cl2N2O2P
Molecular weight	261.08
InChIKey	CMSMOCZEIVJLDB-UHFFFAOYSA-N

SMILES: C1CNP(=O)(OC1)N(CCCl)CCCl

IUPAC name: N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine

ChEBI definition: A phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom.

Pharmacological roles (ChEBI): carcinogenic agent, alkylating agent, immunosuppressive agent, antineoplastic agent, antirheumatic drug, drug allergen.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Anhydrous cyclophosphamide, Ciclofosfamida, Cyclophosphamide (anhydrous), Cyclophosphamide anhydrous, Cyclophosphamide lyophilized, Cyclophosphamide, anhydrous, cyclophosphamide, cyclophosfamide, Cytophosphane, SID50105634, Cyclo-phosphamide

Parent form; salt/anhydrous children: CHEMBL1200796, CHEMBL2364721

Patent coverage: 75,852 distinct patent families (283,534 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 283,508 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Neuropeptide S receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NPSR1	5.4	Potency	3981	nM	CHEMBL_ACT_4917137

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3,334.

Phase distribution

(phase/status distribution below is over 2,600 sampled trials of the 3,334 total).

Phase	Trials
PHASE2	1,387
PHASE3	537
PHASE1/PHASE2	411
PHASE1	124
PHASE2/PHASE3	76
PHASE4	60
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03892330	PHASE4	NOT_YET_RECRUITING	Combination Therapy of Anthracyclines for Children With Nephroblastoma
NCT05207358	PHASE4	RECRUITING	Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
NCT05300932	PHASE4	ACTIVE_NOT_RECRUITING	A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
NCT05420454	PHASE4	RECRUITING	A Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420467	PHASE4	RECRUITING	A Study for the Adjuvant Treatment of Breast Cancer
NCT05518383	PHASE4	RECRUITING	B-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT07077486	PHASE4	RECRUITING	Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT00003398	PHASE4	COMPLETED	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00131313	PHASE4	UNKNOWN	Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00198978	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198991	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004	PHASE4	COMPLETED	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199017	PHASE4	COMPLETED	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT00199056	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199082	PHASE4	COMPLETED	Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT00199095	PHASE4	COMPLETED	Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT00307671	PHASE4	COMPLETED	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
NCT00339118	PHASE4	UNKNOWN	EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
NCT00399399	PHASE4	UNKNOWN	CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors
NCT00400075	PHASE4	UNKNOWN	CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
NCT00494897	PHASE4	COMPLETED	PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT00526175	PHASE4	COMPLETED	LAL-BR/2001: Study Treatment to Low Risk ALL
NCT00526305	PHASE4	COMPLETED	LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
NCT00526409	PHASE4	COMPLETED	LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
NCT01088724	PHASE4	COMPLETED	Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
NCT01088750	PHASE4	COMPLETED	Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
NCT01199432	PHASE4	COMPLETED	Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
NCT01271010	PHASE4	TERMINATED	A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
NCT01283386	PHASE4	TERMINATED	A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
NCT01339988	PHASE4	UNKNOWN	Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
NCT01358253	PHASE4	COMPLETED	Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
NCT01537029	PHASE4	COMPLETED	Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01746992	PHASE4	UNKNOWN	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
NCT01861561	PHASE4	TERMINATED	Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
NCT01995331	PHASE4	UNKNOWN	Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
NCT02412423	PHASE4	COMPLETED	Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors
NCT02419742	PHASE4	COMPLETED	Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
NCT02549677	PHASE4	COMPLETED	Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02627248	PHASE4	UNKNOWN	Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
NCT02645565	PHASE4	COMPLETED	Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis
NCT02752815	PHASE4	UNKNOWN	Reduced Chemotherapy in Low Risk DLBCL
NCT02858804	PHASE4	COMPLETED	EDOCH Alternating With DHAP for New Diagnosed Younger MCL
NCT02894645	PHASE4	UNKNOWN	Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT02903524	PHASE4	UNKNOWN	Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
NCT03123770	PHASE4	UNKNOWN	Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients
NCT03171831	PHASE4	UNKNOWN	Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
NCT03218852	PHASE4	UNKNOWN	Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
NCT03384277	PHASE4	COMPLETED	Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
NCT03817853	PHASE4	COMPLETED	An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
NCT04009525	PHASE4	COMPLETED	Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
NCT04182568	PHASE4	UNKNOWN	Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer
NCT04612582	PHASE4	UNKNOWN	Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
NCT04762810	PHASE4	UNKNOWN	A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis
NCT05108805	PHASE4	COMPLETED	Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
NCT05302336	PHASE4	UNKNOWN	AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
NCT05495893	PHASE4	UNKNOWN	MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN
NCT05666336	PHASE4	UNKNOWN	Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
NCT00070564	PHASE3	ACTIVE_NOT_RECRUITING	S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
NCT00379340	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms’ Tumor
NCT00392327	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00433420	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
NCT00433511	PHASE3	ACTIVE_NOT_RECRUITING	Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
NCT00572169	PHASE3	ACTIVE_NOT_RECRUITING	UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT01057069	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01646034	PHASE3	ACTIVE_NOT_RECRUITING	High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
NCT01704716	PHASE3	RECRUITING	High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01949129	PHASE2/PHASE3	RECRUITING	Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT02003222	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02048813	PHASE3	ACTIVE_NOT_RECRUITING	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02101853	PHASE3	ACTIVE_NOT_RECRUITING	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02112916	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02166463	PHASE3	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02176967	PHASE3	ACTIVE_NOT_RECRUITING	Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02306161	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02405676	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	BNHL-2015 for Children or Adolescents in China
NCT02443077	PHASE3	ACTIVE_NOT_RECRUITING	Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02488967	PHASE3	ACTIVE_NOT_RECRUITING	Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02567435	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02641847	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
NCT02661503	PHASE3	ACTIVE_NOT_RECRUITING	HD21 for Advanced Stages
NCT02724163	PHASE3	RECRUITING	International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
NCT02845882	PHASE3	ACTIVE_NOT_RECRUITING	LBL-2016 for Children or Adolescents in China
NCT03007147	PHASE3	ACTIVE_NOT_RECRUITING	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03020030	PHASE3	ACTIVE_NOT_RECRUITING	Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03117751	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03126916	PHASE3	RECRUITING	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03150693	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03206671	PHASE3	ACTIVE_NOT_RECRUITING	Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
NCT03477500	PHASE3	ACTIVE_NOT_RECRUITING	Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
NCT03480360	PHASE3	ACTIVE_NOT_RECRUITING	Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators’ Expression
NCT03595592	PHASE3	ACTIVE_NOT_RECRUITING	Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03643276	PHASE3	RECRUITING	Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03818334	PHASE2/PHASE3	RECRUITING	Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
NCT03914625	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03937544	PHASE2/PHASE3	RECRUITING	Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
NCT03959085	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03984448	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 124 clinical and 426 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).